Literature DB >> 22325093

Over-expression of wild-type p53-induced phosphatase 1 confers poor prognosis of patients with gliomas.

Chaohui Liang1, Erkun Guo, Shengkui Lu, Shuai Wang, Chunsheng Kang, Liang Chang, Liqiang Liu, Guangyu Zhang, Zhendong Wu, Zongmao Zhao, Shucheng Ma, Liqun Wang, Bao-Hua Jiao.   

Abstract

Wild-type p53-induced phosphatase 1 (Wip1) is a member of the protein phosphatase 2C family, which is characterized by distinctive oncogenic properties. Overexpression of Wip1 is observed in certain types of human tumors that are associated with significantly poor prognosis. This study aimed to detect the expression of Wip1 in gliomas and to analyze its prognostic value in the patients. Wip1 mRNA and protein expression profiles in 81 gliomas and 15 normal brain tissues were detected using RT-PCR, Western blot and immunohistochemistry. The specimens were stained with proliferating cell nuclear antigen (PCNA) and p53 and evaluated using immunohistochemistry. Detailed clinical and demographic information of patients were retrospectively collected until 5years post-operation. Kaplan-Meier survival and Cox's regression analyses were performed to evaluate the prognosis of patients. Wip1-positive expression was observed in the majority of glioma tissues, whereas no Wip1 expression was detected in the normal brain tissues. Wip1-positive expression significantly correlated with glioma histological grade. The PCNA index was higher in the Wip1-positive group compared to that in the Wip1-negative group. A univariate analysis and log-rank test indicated that statistically significant association between Wip1 expression and the lower overall survival rate in the patients with glioma. A multivariate analysis also indicated a statistically significant association between increased Wip1 expression and lower overall survival rate. Our results suggest that Wip1 may be related to pathological diagnosis and prognosis evaluation for malignant gliomas. Crown
Copyright © 2011. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22325093     DOI: 10.1016/j.brainres.2011.12.052

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  14 in total

1.  Discovery of Novel Small-Molecule Scaffolds for the Inhibition and Activation of WIP1 Phosphatase from a RapidFire Mass Spectrometry High-Throughput Screen.

Authors:  Victor Clausse; Yuhong Fang; Dingyin Tao; Harichandra D Tagad; Hongmao Sun; Yuhong Wang; Surendra Karavadhi; Kelly Lane; Zhen-Dan Shi; Olga Vasalatiy; Christopher A LeClair; Rebecca Eells; Min Shen; Samarjit Patnaik; Ettore Appella; Nathan P Coussens; Matthew D Hall; Daniel H Appella
Journal:  ACS Pharmacol Transl Sci       Date:  2022-09-28

2.  WIP1 regulates the proliferation and invasion of nasopharyngeal carcinoma in vitro.

Authors:  Yongquan Zhang; Hong Sun; Guangxiang He; An Liu; Fengjun Wang; Lu Wang
Journal:  Tumour Biol       Date:  2014-05-07

3.  Expression and Prognostic Significance of p53 in Glioma Patients: A Meta-analysis.

Authors:  Yueling Jin; Weizhong Xiao; Tingting Song; Guangjia Feng; Zhensheng Dai
Journal:  Neurochem Res       Date:  2016-04-02       Impact factor: 3.996

4.  A suppressive role of ionizing radiation-responsive miR-29c in the development of liver carcinoma via targeting WIP1.

Authors:  Bo Wang; Dongping Li; Corinne Sidler; Rocio Rodriguez-Juarez; Natasha Singh; Mieke Heyns; Yaroslav Ilnytskyy; Roderick T Bronson; Olga Kovalchuk
Journal:  Oncotarget       Date:  2015-04-30

Review 5.  Cooperative integration between HEDGEHOG-GLI signalling and other oncogenic pathways: implications for cancer therapy.

Authors:  Silvia Pandolfi; Barbara Stecca
Journal:  Expert Rev Mol Med       Date:  2015-02-09       Impact factor: 5.600

6.  Combination of lentivirus-mediated silencing of PPM1D and temozolomide chemotherapy eradicates malignant glioma through cell apoptosis and cell cycle arrest.

Authors:  Peng Wang; Jing-An Ye; Chong-Xian Hou; Dong Zhou; Sheng-Quan Zhan
Journal:  Oncol Rep       Date:  2016-09-14       Impact factor: 3.906

7.  Expression of wild-type p53-induced phosphatase 1 in diabetic epiretinal membranes.

Authors:  Jiping Xu; Haibin Zhong; Ling Cui; Qianqian Lan; Lifei Chen; Wenjing He; Yu Wu; Li Jiang; Hui Huang; Xin Zhao; Li Li; Siming Zeng; Min Li; Fan Xu
Journal:  Oncotarget       Date:  2017-05-30

8.  Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint.

Authors:  Petra Kleiblova; Indra A Shaltiel; Jan Benada; Jan Ševčík; Soňa Pecháčková; Petr Pohlreich; Emile E Voest; Pavel Dundr; Jiri Bartek; Zdenek Kleibl; René H Medema; Libor Macurek
Journal:  J Cell Biol       Date:  2013-05-06       Impact factor: 10.539

9.  Association between overexpression of Wip1 and prognosis of patients with non-small cell lung cancer.

Authors:  Min Zhao; Hongbin Zhang; Guiyun Zhu; Jian Liang; Ning Chen; Yonghui Yang; Xiangcun Liang; Hongmei Cai; Wei Liu
Journal:  Oncol Lett       Date:  2016-02-18       Impact factor: 2.967

10.  Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3.

Authors:  Sona Pechackova; Kamila Burdova; Jan Benada; Petra Kleiblova; Gabriela Jenikova; Libor Macurek
Journal:  Oncotarget       Date:  2016-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.